Skip to content

This website is a third-party information service. It does not provide medical care or operate a treatment facility.

Cancer Biologic Trials

Cleveland, Ohio

Cancer biologic therapy trials in Cleveland, OH

45 cancer biologic therapy studies are recruiting participants at sites in Cleveland as of November 18, 2026, according to ClinicalTrials.gov. Cancer Biologic Trials can help you understand your options and connect with a study team.

Call (888) 343-5902
  • No cost to ask
  • Taking part is voluntary
  • Studies are independently reviewed

Cleveland at a glance

  • 45 studies are recruiting at a site in Cleveland.
  • By phase: Phase 1 (1), Phase 1/2 (8), Phase 2 (15), Phase 2/3 (2), Phase 3 (18), No phase (1). Studies of devices and behavioral approaches have no phase.
  • By sponsor: industry (20), government (16), university, hospital or other (9).
  • By research area: Lymphoma (20), Lung Cancer (14), Breast Cancer (6), Melanoma (3), Prostate Cancer (2).
  • Most recent update to one of these records: November 18, 2026.

Breast cancer studies recruiting in Cleveland

Basic details from each study's public record (the 30 most recently updated of 45). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.

  1. Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

    • Phase 2
    • All ages
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Case Western Reserve University
    Registry record
    NCT05564377 · updated
  2. Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    MetroHealth Medical Center
    Registry record
    NCT06058377 · updated

Source: ClinicalTrials.gov. Data processed . See every breast cancer study recruiting in Cleveland, OH on ClinicalTrials.gov.

Lung cancer studies recruiting in Cleveland

  1. Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Summit Therapeutics
    Registry record
    NCT06767514 · updated
  2. Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Case Western Reserve University
    Registry record
    NCT06287775 · updated
  3. Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Cleveland Clinic Cancer Center/Fairview Hospital · Cleveland Clinic Foundation · MetroHealth Medical Center
    Registry record
    NCT04267848 · updated
  4. Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial

    • Phase 3
    • Ages 70 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Case Western Reserve University · MetroHealth Medical Center
    Registry record
    NCT06096844 · updated
  5. A Study of Intismeran Autogene (V940)/Placebo + Pembrolizumab and Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer (V940-013)

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    Cleveland Clinic - Ohio ( Site 0016)
    Registry record
    NCT07221474 · updated
  6. Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Case Western Reserve University · Cleveland Clinic Foundation
    Registry record
    NCT04181060 · updated
  7. A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    Johnson & Johnson Enterprise Innovation Inc.
    Study site
    University Hospitals Cleveland Medical Center
    Registry record
    NCT06667908 · updated
  8. A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy

    • Phase 3
    • All ages
    • All sexes
    Sponsor
    Pierre Fabre Medicament
    Study site
    Cleveland Clinic Foundation (Adults and Pediatrics)
    Registry record
    NCT03394365 · updated
  9. Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)

    • Phase 2/3
    • Ages 18 and older
    • All sexes
    Sponsor
    SWOG Cancer Research Network
    Study site
    Louis Stokes Cleveland VA Medical Center
    Registry record
    NCT06616584 · updated

Source: ClinicalTrials.gov. Data processed . See every lung cancer study recruiting in Cleveland, OH on ClinicalTrials.gov.

Prostate cancer studies recruiting in Cleveland

  1. A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)

    • Phase 3
    • Ages 18 and older
    • Male participants
    Sponsor
    Janssen Research & Development, LLC
    Study site
    University Hospital of Cleveland
    Registry record
    NCT07164443 · updated

Source: ClinicalTrials.gov. Data processed . See every prostate cancer study recruiting in Cleveland, OH on ClinicalTrials.gov.

Melanoma studies recruiting in Cleveland

  1. SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Immatics US, Inc.
    Study site
    Cleveland Clinic, Taussig Cancer Institute
    Registry record
    NCT06743126 · updated

Source: ClinicalTrials.gov. Data processed . See every melanoma study recruiting in Cleveland, OH on ClinicalTrials.gov.

Lymphoma studies recruiting in Cleveland

  1. Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

    • Phase 2
    • Up to 365 days
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Rainbow Babies and Childrens Hospital
    Registry record
    NCT06317662 · updated
  2. Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Case Western Reserve University
    Registry record
    NCT06337318 · updated
  3. A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study sites
    Cleveland Clinic Main ( Site 0101) · Fairview Hospital-Moll Cancer Center ( Site 0198) · University Hospitals of Cleveland ( Site 0155)
    Registry record
    NCT06890884 · updated
  4. A Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008)

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    University Hospitals of Cleveland ( Site 0113)
    Registry record
    NCT07519772 · updated
  5. A Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007)

    • Phase 2/3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    University Hospitals of Cleveland ( Site 1321)
    Registry record
    NCT07634471 · updated
  6. Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Cleveland Clinic Cancer Center/Fairview Hospital · Cleveland Clinic Foundation
    Registry record
    NCT04269902 · updated
  7. A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

    • Phase 2
    • Ages 1 to 30
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Rainbow Babies and Childrens Hospital
    Registry record
    NCT04546399 · updated
  8. A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab

    • Phase 3
    • Ages 5 to 60
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Cleveland Clinic Foundation · Rainbow Babies and Childrens Hospital
    Registry record
    NCT05675410 · updated
  9. Testing the Anti-cancer Drug, Glofitamab, in Patients With Mantle Cell Lymphoma (A Type of Blood Cancer) Whose Disease Returned After CAR-T Cell Therapy

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Case Western Reserve University
    Registry record
    NCT07003295 · updated
  10. Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Case Western Reserve University
    Registry record
    NCT06649812 · updated
  11. A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
    Study site
    Cleveland Clinic
    Registry record
    NCT07015242 · updated
  12. A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Lyell Immunopharma, Inc.
    Study site
    Cleveland Clinical Taussig Cancer Center
    Registry record
    NCT07188558 · updated
  13. Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia

    • Phase 3
    • Ages 18 to 39
    • All sexes
    Sponsor
    Alliance for Clinical Trials in Oncology
    Study sites
    Case Western Reserve University · Cleveland Clinic Foundation
    Registry record
    NCT03150693 · updated
  14. Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    Allogene Therapeutics
    Study site
    Cleveland Clinic
    Registry record
    NCT06500273 · updated
  15. A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)

    • Phase 2
    • From 366 days, up to 46 years
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Rainbow Babies and Childrens Hospital
    Registry record
    NCT06124157 · updated
  16. Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Case Western Reserve University
    Registry record
    NCT06015880 · updated
  17. Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    SWOG Cancer Research Network
    Study site
    Case Western Reserve University
    Registry record
    NCT05633615 · updated

Source: ClinicalTrials.gov. Data processed . See every lymphoma study recruiting in Cleveland, OH on ClinicalTrials.gov.

Ask about studies near Cleveland

Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.

How should we reach you?
Add a message or the best time to reach you (optional)

Please do not include detailed medical information.

Before you contact a study

More locations in Ohio

About these listings

These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 18, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded. This site lists only studies that test a biologic, such as a vaccine, an antibody, or a cell or gene therapy, as each study is coded in the registry.

Cancer Biologic Trials does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.

Sources and further reading

Ask about a study

A coordinator will contact you. Asking does not commit you to anything.

Call (888) 343-5902

or send a short form

How should we reach you?

Call